> Detailanzeige

Colini Baldeschi, Arianna [Verfasser:in]; Zattoni, Marco [Verfasser:in]; Carloni, Paolo [Verfasser:in]; Bolognesi, Maria Laura [Verfasser:in]; De Vivo, Marco [Verfasser:in]; Legname, Giuseppe [Verfasser:in]; Vanni, Silvia [Verfasser:in]; Nikolic, Lea [Verfasser:in]; Ferracin, Chiara [Verfasser:in]; La Sala, Giuseppina [Verfasser:in]; Summa, Maria [Verfasser:in]; Bertorelli, Rosalia [Verfasser:in]; Bertozzi, Sine Mandrup [Verfasser:in]; Giachin, Gabriele [Verfasser:in]

Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance
  • Beteiligte: Colini Baldeschi, Arianna [Verfasser:in]; Zattoni, Marco [Verfasser:in]; Carloni, Paolo [Verfasser:in]; Bolognesi, Maria Laura [Verfasser:in]; De Vivo, Marco [Verfasser:in]; Legname, Giuseppe [Verfasser:in]; Vanni, Silvia [Verfasser:in]; Nikolic, Lea [Verfasser:in]; Ferracin, Chiara [Verfasser:in]; La Sala, Giuseppina [Verfasser:in]; Summa, Maria [Verfasser:in]; Bertorelli, Rosalia [Verfasser:in]; Bertozzi, Sine Mandrup [Verfasser:in]; Giachin, Gabriele [Verfasser:in]
  • Erschienen: ACS, 2022
  • Erschienen in: Journal of medicinal chemistry 65(13), 8998 - 9010 (2022). doi:10.1021/acs.jmedchem.2c00205
  • Sprache: Englisch
  • DOI: https://doi.org/10.1021/acs.jmedchem.2c00205
  • ISSN: 0022-2623; 0095-9065; 1943-2992; 1520-4804
  • Entstehung:
  • Anmerkungen: Diese Datenquelle enthält auch Bestandsnachweise, die nicht zu einem Volltext führen.
  • Beschreibung: Prion diseases are a group of neurodegenerative disorders characterized by the accumulation of misfolded prion protein (called PrPSc). Although conversion of the cellular prion protein (PrPC) to PrPSc is still not completely understood, most of the therapies developed until now are based on blocking this process. Here, we propose a new drug strategy aimed at clearing prions without any direct interaction with neither PrPC nor PrPSc. Starting from the recent discovery of SERPINA3/SerpinA3n upregulation during prion diseases, we have identified a small molecule, named compound 5 (ARN1468), inhibiting the function of these serpins and effectively reducing prion load in chronically infected cells. Although the low bioavailability of this compound does not allow in vivo studies in prion-infected mice, our strategy emerges as a novel and effective approach to the treatment of prion disease.
  • Zugangsstatus: Freier Zugang